drugset / Trial / NCT06026774
Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Subjects With Resected Digestive System Neoplasms
Phase 1
Recruiting
20 enrolled
Sir Run Run Shaw Hospital
Hangzhou Neoantigen Therapeutics Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the safety, feasibility, and efficacy of personalized mRNA vaccine iNeo-Vac-R01 with standard adjuvant therapy in subjects with surgically resected digestive system neoplasms.
Timeline
- Start
- 2023-09-08
- Primary completion
- 2027-08-31
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | iNeo-Vac-R01 | Messenger RNA (mRNA) | — | Other |